Role of eosinophils in immune-related adverse events from CAR-T therapy
Official title: The Role of Eosinophils in Immunotherapy-Related Adverse Events (irAEs)
Funded at Seattle Children's Hospital · NIH-11432529 · Data updated 2026-11-12
This grant explores how eosinophils contribute to serious side effects like IEC-HS and ICANS in patients receiving CAR-T cancer therapy, with the goal of preventing these toxic events.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 7, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $793,012 |
| NIH project number | 1R01CA317772-01 |
| Project ID | NIH-11432529 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients receiving or eligible for CAR-T cell therapy and those with immune-related adverse events may be most relevant to this research.
✕Less likely to help
Patients not undergoing CAR-T therapy or not at risk for IEC-HS/ICANS may have limited direct benefit.
What this research studies
People with cancer who receive CAR-T cell therapy could benefit if we can prevent serious side effects. The project uses mouse models and clinical samples to study how pre-existing immune signals and CAR-T–driven inflammation lead to eosinophil-driven tissue damage. Researchers will test whether reducing eosinophils can lessen toxicity and improve safety of CAR-T treatments. The findings could guide future strategies to predict and prevent adverse events in patients undergoing CAR-T therapy.
Why it matters
Potential benefit: If successful, the work could reduce life-threatening toxicities from CAR-T therapy, making the treatment safer for more patients.
How similar studies have gone: Preclinical work in animal models and analyses of clinical samples suggest eosinophils play a role, but this connection is still being established.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Gustafson, Heather Leigh Herd — Seattle Children's Hospital
- Study coordinator: Gustafson, Heather Leigh Herd
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.